Logo

Home

smallArrow

Stocks Screener

smallArrow

Marksans Pharma

Marksans Pharma Share Price

Marksans Pharma (INR)318.3543.9   (16%)

Exchange ScripsBSE524404NSEMARKSANSISININE750C01026

Stock Performance
Fundamentals
Technicals
Shareholding Patterns
Financials
Similar Stocks

Trendline of performance -

Marksans Pharma Performance

Market performance
Open price276
High328.8
Volumes28498783
Prev Close318.35
Low276
Closing date2024-09-20
Historical performance
1 Year High328.80
3 Year High328.80
5 Year High328.80
1 Year Low97.45
3 Year Low38.60
5 Year Low9.85

Marksans Pharma Fundamentals

Company Valuation
Market Cap
Market Cap (₹Cr)
7654
Face Value
Face Value (₹)
1
P/E Ratio
P/E Ratio
45.99
Dividend Yield
Dividend Yield
0.19 %

Marksans Pharma Investment Returns

1 Year
208.6%
3 Years
359.4%
5 Years
2223.7%
10 Years
413.5%

Marksans Pharma Technicals

IndicatorsValueSignal
5-DMA292.82Bullish
10-DMA280.49Bullish
20-DMA262.72Bullish
50-DMA225.88Bullish
100-DMA194.33Bullish
200-DMA176.02Bullish

Shareholding Pattern

FieldJun-2024Mar-2024Dec-2023Sep-2023Jun-2023
Promoters22222
Foreign Investors---------------
Domestic Investors22222
Public Investors235498254697237375207935188445
Government---------------

Marksans Pharma Financials

Below figures are in Rs. Crores

ParticularsMar-2024Mar-2023Mar-2022Mar-2021
Other Income50459341967
Operating Profit5090398630073463
Interest112918480
Depreciation743519448362
Profit Before Tax4235337724753022
Consolidated Net Profit3137266318462359
Adjusted EPS7656

Balance Sheet

Below figures are in Rs. Crores

ParticularsMar-2024Mar-2023Mar-2022Mar-2021
Share Capital453453409409
Total Reserves2019716998106828456
Minority Interest209199207189
Total Non-Current Liabilities2052843571237
Total Liabilities26810219041660112280
Capital Work in Progress5472756
Total Assets26810219041660112280

Cash Flow

Below figures are in Rs. Crores

ParticularsMar-2024Mar-2023Mar-2022Mar-2021
Cash Flow from Operating Activities230423749931786
Cash Flow from Investing Activities-1408-2592-844-448
Cash Flow from Financing Activitie-6871978795-153
Net Cash Inflow / Outflow20817609441185
0%
Negative
Neutral
Positive
  • The stock has a PE ratio of 45.99.
  • 3Y Stock Price CAGR of the stock is 66.0.
  • The stock has a beta of 1.0.
  • In the last financial year, the company had an EBITDA of ₹5090 Million.
  • The company generated revenue of ₹21774 Million in the previous financial year.

Marksans Pharma

318.3543.9   (16%)

Investment Amount: ₹ 10410
Current Value: ₹ 31835
Performence: 205.8%
P/L: ₹ 21425
Top Gainers
SymbolChange%
ITDCEM562.45(19%)
MARKSANS318.35(16%)
CONCORDBIO2601.1(16%)
MAGADSUGAR957.45(14%)
PRSMJOHNSN219.54(12%)
Top Losers
SymbolChange%
ROSSELLIND170.85(-73%)
SADHNANIQ59.21(-9%)
BHARATRAS11914.5(-7%)
PEARLPOLY42.08(-7%)
SAKSOFT276.15(-7%)
AGIIL1042.6(-6%)
GATECH1.17(-6%)
XTGLOBAL41.63(-6%)
Similar stocks

Panacea Biotec

▲ 62.2

314.09

August 20 - September 20

Concord Biotech

▲ 57.1

2601.1

August 20 - September 20

Syncom Formulations

▲ 39.5

22.71

August 20 - September 20

Wanbury

▲ 38.6

278.79

August 20 - September 20

Jubilant Pharmova

▲ 34.5

1206.1

August 20 - September 20

Brooks Laboratories

▲ 33.6

147.47

August 20 - September 20

Nectar Lifesciences

▲ 29.9

42.25

August 20 - September 20

Biofil Chem & Pharma

▲ 29.7

83.6

August 20 - September 20

Announcing Stock of the Month!

 

Phone

Registered Users

10 lacs

Google Rating

4.6